Pamisell has ranked among the top searched stocks for 16 days in the past month.
As of 12:30 PM on the 27th, Pamisell is trading at 16,550 KRW, down 2.36% from the previous day. This represents a 15.13% decline compared to October 6. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Today, foreigners have tentatively net purchased 74,336 shares. Over the past five days, individual investors have net purchased 174,822 shares, while foreigners and institutions have net sold 82,525 shares and 101,827 shares, respectively.
On October 25, Pamisell was a market topic with the headline "Rising Close on FDA Approval of Remdesivir in the US."
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
